Platelets and atherosclerosis.
Platelets and atherosclerosis.
复制标题
血小板和动脉粥样硬化。
DOI：
10.1016/0002-9343(81)90144-3
复制
发表时间：
1981
期刊：
影响因子：
--
通讯作者：
Nachman,RL
中科院分区：
文献类型：
--
作者：
Weksler,BB;Nachman,RL
1989年6月，吕贝克医科大学神经病学系组织了一次关于血小板-血管壁相互作用的国际研讨会。这次研讨会的目的是什么？我们认为，血栓形成基础研究与其临床应用之间的差距越来越大。治疗血栓栓塞并发症患者的传统策略必须受到严格质疑。临床试验表明，阿司匹林在1000毫克/天或更高的高剂量能够预防短暂性脑缺血发作患者的中风。然而，在分子水平上对阿司匹林的作用机制的研究导致了对高剂量阿司匹林的抗血栓作用的怀疑，因为它似乎实际上促进了血栓形成。除阿司匹林外，临床上用于预防心血管并发症的大多数药物都是血小板聚集抑制剂。该临床策略基于血小板在动脉粥样硬化及其并发症的发展中起主要作用的假设。作为最新的结果，在这卷显示，巨噬细胞和血管壁因子现在被认为在动脉粥样硬化中发挥重要作用，一个新的治疗方法应旨在影响这些途径。吕贝克研讨会的另一个重要结果是，血小板的放射性标记被确立为一种公认的实验室方法，用于评价血小板与血管壁的相互作用（见M.戈德曼湖Harker，and MK Dewanjee in this volume）.因此，有一个适当的方法在体内定量血小板沉积在血管段。放射性标记血小板的注射允许不同抗血栓药物的体内测试。
In June 1989, the Department of Neurology of the Medical University of Lubeck organized an international symposium on Platelet-Vessel Wall Interaction. What was the purpose of this symposium? We felt that there was an ever-increasing gap between basic thrombosis research and its clinical applications. Traditional strategies for treating patients with thromboembolic complications had to be questioned critically. Clinical trials have demonstrated that aspirin in a high dosage of 1000 mg per day or more is able to prevent stroke in patients with transient ischemic attacks. The research on the mechanism of action of aspirin at the molecular level has led, however, to doubts about the antithrombotic effect of high-dosage aspirin, as it seems actually to further thrombogenicity.An explanation for this" aspirin dilemma" has yet to be formulated. Apart from aspirin, most drugs used clinically for preventing cardiovascular complications work as platelet aggregation inhibitors. This clinical strategy proceeds on the assumption that platelets play the predominant role in the development of atherosclerosis and its complications. As the latest results presented in this volume show, macrophages and vessel wall factors are now thought to play an important role in atherosclerosis and a new therapeutic approach should aim at influencing these pathways. Another important result of the Lubeck Symposium was that radiolabeling of platelets was established as an accepted laboratory method for evaluating the interaction of the platelets with the vessel wall (see the contributions by M. Goldman, L. Harker, and MK Dewanjee in this volume). There is thus an appropriate method for the in vivo quantification of platelet deposits in vessel segments. The injection of radiolabeled platelets allows the in vivo testing of different antithrombotic drugs.